# reload+after+2024-01-22 06:47:34.255561
address1§314 Main Street
address2§Suite 04-200
city§Cambridge
state§MA
zip§02142
country§United States
phone§857 400 9491
website§https://theseusrx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
fullTimeEmployees§38
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Iain D. Dukes DPHIL, M.A.', 'age': 65, 'title': 'Co-Founder & Chairman', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 67285, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bradford D. Dahms', 'age': 35, 'title': 'President, CFO & Director', 'yearBorn': 1988, 'fiscalYear': 2022, 'totalPay': 480950, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kristine  Callahan CPA', 'title': 'VP & Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§4
boardRisk§9
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§3.994
currency§USD
dateShortInterest§1702598400
forwardEps§-0.94
exchange§NMS
quoteType§EQUITY
shortName§Theseus Pharmaceuticals, Inc.
longName§Theseus Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1633613400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§aeb74a7f-09da-3f98-b34a-9ada5fad9e14
gmtOffSetMilliseconds§-18000000
targetHighPrice§7.0
targetLowPrice§3.5
targetMeanPrice§5.25
targetMedianPrice§5.25
recommendationMean§2.7
recommendationKey§hold
numberOfAnalystOpinions§2
quickRatio§29.291
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
